Shanghai, December 19, 2018 / PR Newswire / -- Recently, Reistone Biopharma Company Limited (“Reistone”) announced that, FDA approved its application for the Crohn’s disease phase II clinical trial of its SHR0302, a novel and small molecule JAK1 inhibitor

SHANGHAI, Oct. 22, 2018 /PRNewswire/ -- Reistone Biopharma Company Limited ( Reistone ), a clinical stage biopharmaceutical company headquartered in Shanghai, today announced the US FDA approval of IND for phase II clinical trial to investigate the effica

Shanghai, October 22, 2018 / PR Newswire / -- On October 18, Reistone Biopharma Company Limited (“Reistone”) officially announced that, FDA approved its application for the phase II clinical trial of its SHR0302, a novel and small molecule JAK1 inhibitor.